Drugs

, Volume 72, Issue 12, pp 1679–1707

Exenatide Extended-Release

A Review of Its Use in Type 2 Diabetes Mellitus
Adis Drug Evaluation

Abstract

Subcutaneous exenatide extended-release (ER; Bydureon™; also known as exenatide once weekly), a glucagon-like peptide-1 receptor agonist, provides a convenient, simple, once-weekly regimen that is approved in adult patients with type 2 diabetes as adjunctive monotherapy to diet plus exercise (in the US; not as first-line therapy) and/or as combination therapy with specific oral antihyperglycaemic drugs (OADs) in patients with inadequately controlled type 2 diabetes despite treatment with these OADs (US and Europe). This article reviews the clinical efficacy and tolerability of exenatide ER in the treatment of adult patients with type 2 diabetes and gives a brief overview of its pharmacological properties.

In several short-term (24–30 weeks) well designed trials, adjunctive subcutaneously injectable exenatide ER once weekly, as monotherapy or in combination with OADs, significantly improved glycaemic control, bodyweight and some surrogate markers of cardiovascular risk in adult patients with inadequately controlled type 2 diabetes despite diet and exercise and/or treatment with OADs. Furthermore, the beneficial effects of adjunctive exenatide ER therapy were sus-tained in extension studies of up to 3 years of treatment. Overall, the intensity of glycaemic control with exenatide ER was generally better than that observed with the exenatide immediate-release formulation (twice daily), sitagliptin or insulin glargine. Exenatide ER was shown to be noninferior to metformin in terms of glycaemic efficacy, but did not meet the criteria for noninferiority versus liraglutide. In treatment-naive patients, exenatide ER treatment did not meet non-inferiority criteria versus pioglitazone, whereas in treatment-experienced patients, exenatide ER provided better glycaemic control than pioglitazone. Improvements in glycaemic control with exenatide ER and, in general, with other antihyperglycaemic agents were reflected in significant improvements from baseline in treatment satisfaction and health-related quality-of-life measures. Exenatide ER was generally well tolerated in patients participating in these trials, with most treatment-emergent adverse events being of a gastrointestinal nature, of mild to moderate severity, transient and of a similar nature and incidence to those occurring with the exenatide immediate-release formulation. Thus, exenatide ER is a useful option for the treatment of type 2 diabetes, particularly in patients where bodyweight loss is an essential aspect of the individual patient’s management.

References

  1. 1.
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35 Suppl. 1: S64–71CrossRefGoogle Scholar
  2. 2.
    American Diabetes Association. Standards of medical care in diabetes: 2012. Diabetes Care 2012; 35 Suppl. 1: S11-63Google Scholar
  3. 3.
    International Diabetes Federation. Global diabetes plan 2011–2021 [online]. Available from URL: http://www.idf.org/sites/default/files/Global_Diabetes_Plan_Final.pdf [Ac-cessed 2012 May 31]
  4. 4.
    May AL, Kuklina EV, Yoon PW. Prevalence of cardio-vascular disease risk factors among US adolescents, 1999–2008. Pediatrics 2012; 129 (6): 1035–41PubMedCrossRefGoogle Scholar
  5. 5.
    Haung ES, Basu A, O’Grady M, et al. Projecting the future diabetes population size and related costs for the US. Diabetes Care 2009; 32 (12): 2225–9CrossRefGoogle Scholar
  6. 6.
    Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–79Google Scholar
  7. 7.
    Bailey C, Kodack M. Patient adherence to medication re-quirements for therapy of type 2 diabetes. Int J Clin Prac 2011; 65 (3): 314–22CrossRefGoogle Scholar
  8. 8.
    Amylin Pharmaceuticals Inc. Bydureon™ exenatide ex-tended-release for injectable suspension: US prescribing information [online]. Available from URL: http://documents.bydureon.com/Bydureon_PI.pdf [Accessed 2012 Apr 23]
  9. 9.
    European Medicines Agency. Bydureon 2mg powder and solvent for prolonged-release suspension for injection: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdf [Accessed 2012 Apr 23]
  10. 10.
    Cvetković RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 2007; 67 (6): 935–54PubMedCrossRefGoogle Scholar
  11. 11.
    Keating GM. Exenatide. Drugs 2005; 65 (12): 1681–92PubMedCrossRefGoogle Scholar
  12. 12.
    Gallwitz Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Drug Focus 2006; 60 (12): 1654–61Google Scholar
  13. 13.
    Joy SV, Rodgers PT, Scates AM. Incretin mimetics as emerging treatments for type 2 diabetes. Ann Pharmacother 2005; 39 (1): 110–8PubMedCrossRefGoogle Scholar
  14. 14.
    Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health-Sys Pharm 2005; 62: 173–81Google Scholar
  15. 15.
    DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) micro-spheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Therap 2011; 13 (11): 1145–54CrossRefGoogle Scholar
  16. 16.
    Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulaion during hypoglycaemia. Diabetes 2004; 53: 2397–403PubMedCrossRefGoogle Scholar
  17. 17.
    Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of ex-enatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30 (6): 1487–93PubMedCrossRefGoogle Scholar
  18. 18.
    Iwamoto K, Nasu R, Yamamura A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of ex-enatide once weekly in Japanese patients with type 2 diabetes. Endocrine J 2009; 56 (8): 951–62CrossRefGoogle Scholar
  19. 19.
    Rayner CK, Samson M, Jones KL, et al. Relationships of upper gastrointestinal control motor and sensory function with glycemic control. Diabetes Care 2001; 24 (2): 371–81PubMedCrossRefGoogle Scholar
  20. 20.
    Drucker DJ, Buse JB, Taylor et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372 (9645): 1240–50PubMedCrossRefGoogle Scholar
  21. 21.
    Diamant M, Van Gaal L, Stranks S, et al. Once weekly ex-enatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375 (9733): 2234–43PubMedCrossRefGoogle Scholar
  22. 22.
    Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012; 35 (2): 252–8. Plus supplementary material available from URL: http://www.care.diabetesjournals.org [Accessed 2012 May 1]PubMedCrossRefGoogle Scholar
  23. 23.
    Diamant M, Van Gaal L, Stranks S, et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 2012; 35 (4): 683-9. Plus supple-mentary material available from URL: http://care.diabetesjournals.org [Accessed 2012 May 10]
  24. 24.
    Sager P, Darpo B, Han J, et al. Exenatide once weekly did not affect corrected QT interval in patients with type 2 diabetes [abstract no. 1070-P]. Diabetes 2011; 60 Suppl. 1: A294Google Scholar
  25. 25.
    Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011; 50 (1): 65–74PubMedCrossRefGoogle Scholar
  26. 26.
    Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376 (9739): 431–9. Plus supplementary material available from URL: http://www.thelancet.com [Accessed 2012 May 1]PubMedCrossRefGoogle Scholar
  27. 27.
    Blevins T, Pullman J, Malloy J, et al. DURATION-5: ex-enatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96 (5): 1301–10PubMedCrossRefGoogle Scholar
  28. 28.
    Ji L, Onishi Y, Ahn CW. Efficacy and safety of exenatide once weekly versus exenatide twice daily in Asian patients with type 2 diabetes [abstract no. P-1144]. 21st World Diabetes Congress; 2011 Dec 4–8; DubaiGoogle Scholar
  29. 29.
    Imaoka T, Inagaki N, Atsumi Y, et al. Exenatide once-weekly compared with insulin glargine in Japanese patients with type 2 diabetes: an open-label randomized trial [abstract no. P-1146]. 21st World Diabetes Congress; 2011 Dec 4–8; DubaiGoogle Scholar
  30. 30.
    Amylin Pharmaceuticals Inc. A study to examine the effects of exenatide once-weekly injection on glucose control and safety in Asian subjects [ClinicalTrials.gov identifier NCT00917267]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 26]
  31. 31.
    Amylin Pharmaceuticals Inc. Study to evaluate the efficacy and safety of exenatide once-weekly injection compared with once-daily insulin in type 2 diabetes mellitus [ClinicalTrials.gov identifier NCT00935532]. US National In-stitutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 May 11]
  32. 32.
    Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010; 33 (6): 1255–61PubMedCrossRefGoogle Scholar
  33. 33.
    Taylor K, Gurney K, Han J, et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 2011 Apr 29; 11: 9Google Scholar
  34. 34.
    Maggs D, Walsh B, Li Y, et al. Exenatide once weekly: sustained improvement in glycaemic control and weight loss through 3 years [abstract no. 783]. Diabetologia 2011; 54 Suppl. 1: S315–6Google Scholar
  35. 35.
    Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily si-tagliptin or pioglitazone to once-weekly exenatide. Diabetic Med 2011; 28 (6): 705–14PubMedCrossRefGoogle Scholar
  36. 36.
    Buse JB, Nauck MA, Forst T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study [abstract no. 75]. Diabetologia 2011; 54 Suppl. 1: S38Google Scholar
  37. 37.
    Bruhn D, Han J, Meloni A, et al. Achieving target goals in patients with T2DM treated with exenatide once weekly or insulin glargine: a retrospective analysis of the number-needed-to-treat [abstract no. PDB10]. Value Health 2011; 14 (7): A473Google Scholar
  38. 38.
    Wintle M, Meloni A, DeYoung MB, et al. Effects of ex-enatide once weekly on glycaemic goals and selected cardiovascular risk factors in patients with type 2 diabetes: a retrospective analysis of pooled clinical trial data [abstract no. 781]. Diabetologia 2011; 54 Suppl. 1: S314–5Google Scholar
  39. 39.
    Horton E, Walsh B, Han J, et al. Improvements in glycaemic control, body weight and markers of cardiovascular risk and hepatic injury are demonstrated after 52 weeks’ treat-ment with exenatide once weekly [abstract no. P126]. Diabet Med 2011; 28 Suppl. 1: 71Google Scholar
  40. 40.
    Malone J, Walsh B, Pencek R, et al. Efficacy and safety of exenatide once weekly across background therapies: a pooled analysis of DURATION studies [abstract no. 1066-P]. Diabetes 2011; 60 Suppl. 1: A293Google Scholar
  41. 41.
    Brunell SC, Blickensderfer A, Pencek R, et al. Clinical out-comes in patients with type 2 diabetes treated with exenatide twice daily or once weekly: retrospective analysis of pooled clinical data stratified by body mass index [abstract Diabetes 2011; 60 Suppl. 1: A283-4Google Scholar
  42. 42.
    Pencek R, Blickensderfer A, Li Y, et al. Clinical outcomes in patients with type 2 diabetes treated with exenatide twice daily or once weekly: retrospective analysis of pooled clinical data stratified by age and duration of diabetes [abstract no. 1033-P]. Diabetes 2011; 60 Suppl. 1: A283Google Scholar
  43. 43.
    Horton E, Taylor K, Booker Porter T, et al. Once-weekly exenatide used for six months provided improved glycaemic control and weight loss compared with sitagliptin, pioglitazone or insulin glargine in metformin-treated patients with type 2 diabetes [abstract no. P125]. Diabet Med 2011; 28 Suppl. 1: 70–1Google Scholar
  44. 44.
    Blickensderfer A, Pencek R, Li Y, et al. Exenatide once weekly: a retrospective analysis of pooled exenatide clinical trial efficacy data stratified by race, age, duration of diabetes, BMI and gender [abstract no. 782]. Diabetologia 2011; 54 Suppl. 1: S315Google Scholar
  45. 45.
    Boardman MK, Hanefeld M, Kumar A, et al. DURATION-4: improvements in glucose control and cardio-vascular risk factors in patients with type 2 diabetes treated with exenatide once weekly, metformin, pioglitazone, or sitagliptin [abstract no. 779]. Diabetologia 2011; 54 Suppl. 1: S314Google Scholar
  46. 46.
    Diamant M, VanGaal L, Stranks S, et al. DURATION-3: changes in cardiovascular risk factors observed in patients with type 2 diabetes after 84-week therapy with exenatide once weekly or insulin glargine [abstract no. 778]. Diabetologia 2011; 54 Suppl. 1: S313Google Scholar
  47. 47.
    Chalasani NP, Anderson PW, Han J, et al. Effect of once weekly exenatide on ALT and cardiometabolic risk factors in adults with type 2 diabetes [abstract no. 661]. Hepatology 2010; 52 (4 Suppl.): 637AGoogle Scholar
  48. 48.
    Paul S, Best J, Klein K, et al. Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide. Diabetes Obes Metab 2012; In pressGoogle Scholar
  49. 49.
    Peskin BR, Shcheprov AV, Boye KS, et al. Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis. Diabetes Obes Metab 2011; 13 (10): 921–7CrossRefGoogle Scholar
  50. 50.
    Timlin L, Beaudet A, Wilson B, et al. Long-term clinical outcomes of exenatide once-weekly versus insulin glargine for the treatment of type 2 diabetes projected using the Core Diabetes Model [abstract no. PBD9]. Value Health 2010; 13 (7): A284-5Google Scholar
  51. 51.
    Best JH, Boye KS, Rubin RR, et al. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabetic Medicine 2009; 26 (7): 722–8PubMedCrossRefGoogle Scholar
  52. 52.
    Best JH, Rubin RR, Peyrot M, et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care 2011; 34 (2): 314–9PubMedCrossRefGoogle Scholar
  53. 53.
    Gaebler JA, Soto-Campos G, Alperin P, et al. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc Health Risk Manag 2012; 8: 255–64PubMedCrossRefGoogle Scholar
  54. 54.
    Guillermin A-L, Lloyd A, Best JH, et al. Long-term cost-consequence analysis of exenatide once weekly vs si-tagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. J Med Econ 2012; 15 (4): 654–63PubMedCrossRefGoogle Scholar
  55. 55.
    Samyshkin Y, Guillermin A-L, Best JH, et al. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the United States. J Med Econ 2012; In pressGoogle Scholar
  56. 56.
    Ridge T, Moretto T, MacConell L, et al. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes. Diabet Obes Metab 2012; In pressGoogle Scholar
  57. 57.
    Anderson PW, Brown C, Lee D, et al. Changes in kidney function and renal adverse events in clinical trials comparing exenatide once weekly and exenatide twice daily [abstract no. 823]. Diabetologia 2011; 54 Suppl. 1: S334Google Scholar
  58. 58.
    Fineman MS, Mace KF, Diamant M, et al. Clinical re-levance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012; 14 (6): 546–54PubMedCrossRefGoogle Scholar
  59. 59.
    Russell-Jones D. The safety and tolerability of GLP-1 re-ceptor agonists in the treatment of type 2 diabetes. Int J Clin Pract 2010; 64 (10): 1402–14PubMedCrossRefGoogle Scholar
  60. 60.
    Nelson S. Management of patients with type 2 diabetes. Curr Med Res Opin 2011; 27 (10): 1931–47PubMedCrossRefGoogle Scholar
  61. 61.
    Gallwitz Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs 2011; 71 (13): 1675–88Google Scholar
  62. 62.
    Cefalu WT. Evolving treatment strategies for the manage-ment of type 2 diabetes. Am J Med Sci 2012; 343 (1): 21–6PubMedCrossRefGoogle Scholar
  63. 63.
    Gallwitz B. Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus. Drug Saf 2010; 33 (2): 87–100PubMedCrossRefGoogle Scholar
  64. 64.
    Rodbard H, Jellinger P, Davidson J, et al. Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control [published erratum appears in Endocr Pract 2009; 15 (7): 768-70]. Endocr Pract 2009; 15 (6): 540–59PubMedCrossRefGoogle Scholar
  65. 65.
    Lorenzi G, Schreiner Osther J, et al. Application of adult-learning principles to patient instructions: a usability study for an exenatide once-weekly injection device. Clin Dia-betes 2010; 28 (4): 157–62CrossRefGoogle Scholar
  66. 66.
    Amylin Pharmaceuticals Inc. Exenatide Study of Cardio-vascular Event Lowering Trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus [Clinical-Trials.gov identifier NCT01144338]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Apr 26]

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.AdisMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations